Veru (VERU) Competitors

$2.28 +0.06 (+2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$2.25 -0.03 (-1.32%)

As of 07:07 PM Eastern

VERU vs. MED, EL, IPAR, PBH, and HLF

Should you be buying Veru stock or one of its competitors? The main competitors of Veru include Medifast (MED), Estee Lauder Companies (EL), Interparfums (IPAR), Prestige Consumer Healthcare (PBH), and Herbalife (HLF). These companies are all part of the "personal products" industry.

How does Veru compare to Medifast?

Veru (NASDAQ:VERU) and Medifast (NYSE:MED) are both small-cap personal products companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

: Veru presently has a consensus price target of $22.50, suggesting a potential upside of 886.84%. Medifast has a consensus price target of $12.00, suggesting a potential downside of 5.01%. Given Veru's stronger consensus rating and higher possible upside, analysts clearly believe Veru is more favorable than Medifast.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veru
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Medifast
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50
: Veru has a beta of -1.19, indicating that its share price is 219% less volatile than the S&P 500. Comparatively, Medifast has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.
: 47.2% of Veru shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Comparatively, 3.7% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Medifast has higher revenue and earnings than Veru. Medifast is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Veru $16.89M 2.17 -$22.73M -$1.26 N/A
Medifast $385.79M 0.36 -$18.67M -$1.83 N/A
: Veru has a net margin of 0.00% compared to Medifast's net margin of -5.78%. Medifast's return on equity of -4.80% beat Veru's return on equity.
Company Net Margins Return on Equity Return on Assets
Veru N/A -83.63% -55.90%
Medifast -5.78% -4.80% -3.83%
: In the previous week, Medifast had 13 more articles in the media than Veru. MarketBeat recorded 14 mentions for Medifast and 1 mentions for Veru. Medifast's average media sentiment score of 0.02 beat Veru's score of 0.00 indicating that Medifast is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veru
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Medifast
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.17	-$22.73M	-$1.26	N/A
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-83.63%	-55.90%
Medifast	-5.78%	-4.80%	-3.83%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medifast	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Veru and Medifast tied by winning 8 of the 16 factors compared between the two stocks.

How does Veru compare to Estee Lauder Companies?

Estee Lauder Companies (NYSE:EL) and Veru (NASDAQ:VERU) are both personal products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

: Veru has a net margin of 0.00% compared to Estee Lauder Companies' net margin of -1.67%. Estee Lauder Companies' return on equity of 20.66% beat Veru's return on equity.
Company Net Margins Return on Equity Return on Assets
Estee Lauder Companies -1.67% 20.66% 4.15%
Veru N/A -83.63% -55.90%
: In the previous week, Estee Lauder Companies had 51 more articles in the media than Veru. MarketBeat recorded 52 mentions for Estee Lauder Companies and 1 mentions for Veru. Estee Lauder Companies' average media sentiment score of 0.74 beat Veru's score of 0.00 indicating that Estee Lauder Companies is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Estee Lauder Companies
21 Very Positive mention(s)
6 Positive mention(s)
12 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
Veru
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Veru has lower revenue, but higher earnings than Estee Lauder Companies. Estee Lauder Companies is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Estee Lauder Companies $14.33B 2.15 -$1.13B -$0.70 N/A
Veru $16.89M 2.17 -$22.73M -$1.26 N/A
: 55.2% of Estee Lauder Companies shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 13.1% of Estee Lauder Companies shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Estee Lauder Companies currently has a consensus target price of $101.00, suggesting a potential upside of 18.56%. Veru has a consensus target price of $22.50, suggesting a potential upside of 886.84%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Estee Lauder Companies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Estee Lauder Companies
2 Sell rating(s)
9 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.40
Veru
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Estee Lauder Companies has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Veru has a beta of -1.19, meaning that its share price is 219% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Estee Lauder Companies	-1.67%	20.66%	4.15%
Veru	N/A	-83.63%	-55.90%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estee Lauder Companies	21 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estee Lauder Companies	$14.33B	2.15	-$1.13B	-$0.70	N/A
Veru	$16.89M	2.17	-$22.73M	-$1.26	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estee Lauder Companies	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.40
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Estee Lauder Companies beats Veru on 10 of the 17 factors compared between the two stocks.

How does Veru compare to Interparfums?

Interparfums (NASDAQ:IPAR) and Veru (NASDAQ:VERU) are both personal products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

: Interparfums has a net margin of 11.32% compared to Veru's net margin of 0.00%. Interparfums' return on equity of 15.47% beat Veru's return on equity.
Company Net Margins Return on Equity Return on Assets
Interparfums 11.32% 15.47% 10.82%
Veru N/A -83.63% -55.90%
: In the previous week, Interparfums had 15 more articles in the media than Veru. MarketBeat recorded 16 mentions for Interparfums and 1 mentions for Veru. Interparfums' average media sentiment score of 0.50 beat Veru's score of 0.00 indicating that Interparfums is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Interparfums
1 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Veru
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Interparfums has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Interparfums $1.49B 2.02 $168.39M $5.27 17.79
Veru $16.89M 2.17 -$22.73M -$1.26 N/A
: 55.6% of Interparfums shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 43.7% of Interparfums shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Interparfums currently has a consensus target price of $105.20, suggesting a potential upside of 12.22%. Veru has a consensus target price of $22.50, suggesting a potential upside of 886.84%. Given Veru's higher probable upside, analysts plainly believe Veru is more favorable than Interparfums.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interparfums
0 Sell rating(s)
3 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.71
Veru
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Interparfums has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Veru has a beta of -1.19, meaning that its share price is 219% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Interparfums	11.32%	15.47%	10.82%
Veru	N/A	-83.63%	-55.90%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Interparfums	1 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interparfums	$1.49B	2.02	$168.39M	$5.27	17.79
Veru	$16.89M	2.17	-$22.73M	-$1.26	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Interparfums	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Interparfums beats Veru on 14 of the 16 factors compared between the two stocks.

How does Veru compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Veru (NASDAQ:VERU) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

: Prestige Consumer Healthcare currently has a consensus target price of $74.75, suggesting a potential upside of 37.17%. Veru has a consensus target price of $22.50, suggesting a potential upside of 886.84%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Prestige Consumer Healthcare.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prestige Consumer Healthcare
0 Sell rating(s)
4 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.43
Veru
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 1.4% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Prestige Consumer Healthcare has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, Veru has a beta of -1.19, meaning that its share price is 219% less volatile than the S&P 500.
: In the previous week, Prestige Consumer Healthcare had 9 more articles in the media than Veru. MarketBeat recorded 10 mentions for Prestige Consumer Healthcare and 1 mentions for Veru. Prestige Consumer Healthcare's average media sentiment score of 0.72 beat Veru's score of 0.00 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prestige Consumer Healthcare
5 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Veru
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Prestige Consumer Healthcare has a net margin of 16.90% compared to Veru's net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 12.02% beat Veru's return on equity.
Company Net Margins Return on Equity Return on Assets
Prestige Consumer Healthcare 16.90% 12.02% 6.41%
Veru N/A -83.63% -55.90%
: Prestige Consumer Healthcare has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Prestige Consumer Healthcare $1.14B 2.27 $214.60M $3.78 14.42
Veru $16.89M 2.17 -$22.73M -$1.26 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	16.90%	12.02%	6.41%
Veru	N/A	-83.63%	-55.90%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.14B	2.27	$214.60M	$3.78	14.42
Veru	$16.89M	2.17	-$22.73M	-$1.26	N/A

Summary

Prestige Consumer Healthcare beats Veru on 12 of the 15 factors compared between the two stocks.

How does Veru compare to Herbalife?

Veru (NASDAQ:VERU) and Herbalife (NYSE:HLF) are both small-cap personal products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

: In the previous week, Herbalife had 12 more articles in the media than Veru. MarketBeat recorded 13 mentions for Herbalife and 1 mentions for Veru. Herbalife's average media sentiment score of 0.69 beat Veru's score of 0.00 indicating that Herbalife is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veru
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Herbalife
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
: Herbalife has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Herbalife, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Veru $16.89M 2.17 -$22.73M -$1.26 N/A
Herbalife $5.04B 0.30 $228.30M $2.20 6.57
: Herbalife has a net margin of 4.67% compared to Veru's net margin of 0.00%. Herbalife's return on equity of -38.73% beat Veru's return on equity.
Company Net Margins Return on Equity Return on Assets
Veru N/A -83.63% -55.90%
Herbalife 4.67% -38.73% 8.34%
: 47.2% of Veru shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 5.1% of Herbalife shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Veru has a beta of -1.19, meaning that its stock price is 219% less volatile than the S&P 500. Comparatively, Herbalife has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
: Veru presently has a consensus target price of $22.50, indicating a potential upside of 886.84%. Herbalife has a consensus target price of $17.80, indicating a potential upside of 23.14%. Given Veru's stronger consensus rating and higher probable upside, equities research analysts clearly believe Veru is more favorable than Herbalife.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veru
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Herbalife
0 Sell rating(s)

4 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.43

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Herbalife	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.17	-$22.73M	-$1.26	N/A
Herbalife	$5.04B	0.30	$228.30M	$2.20	6.57

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-83.63%	-55.90%
Herbalife	4.67%	-38.73%	8.34%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Herbalife	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Herbalife beats Veru on 10 of the 15 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.63M	$8.31B	$6.30B	$12.15B
Dividend Yield	N/A	2.47%	2.77%	5.24%
P/E Ratio	-1.81	123.69	28.70	27.01
Price / Sales	2.17	8.21	528.47	77.56
Price / Cash	N/A	17.04	43.62	54.08
Price / Book	1.82	3.59	9.87	6.89
Net Income	-$22.73M	$223.69M	$3.54B	$333.00M
7 Day Performance	1.33%	0.22%	1.57%	1.87%
1 Month Performance	-8.06%	13.83%	6.13%	8.64%
1 Year Performance	-54.67%	4.21%	43.01%	43.19%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	1.7578 of 5 stars	$2.28 +2.7%	$22.50 +886.8%	-55.8%	$35.63M	$16.89M	N/A	230	News Coverage Upcoming Earnings
MED Medifast	1.3113 of 5 stars	$10.77 -3.4%	$12.00 +11.5%	-2.0%	$123.01M	$385.79M	N/A	870	Earnings Report Analyst Downgrade
EL Estee Lauder Companies	4.5777 of 5 stars	$77.25 -0.7%	$97.95 +26.8%	+48.2%	$28.15B	$14.33B	N/A	57,000	Earnings Report Dividend Announcement Analyst Forecast
IPAR Interparfums	3.4917 of 5 stars	$91.28 +0.1%	$105.20 +15.2%	-21.0%	$2.92B	$1.49B	17.42	530	News Coverage Earnings Report
PBH Prestige Consumer Healthcare	4.33 of 5 stars	$58.35 -1.0%	$76.50 +31.1%	-33.1%	$2.79B	$1.14B	15.44	540	News Coverage Positive News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors